Reviewed August 28, 2026
Is TB-500 Legal? FDA Status and Licensed Care Options
A committee recommendation is not FDA approval. Here is exactly what changed, and what did not.
The short answer
- FDA status
- Not an FDA-approved drug product
- July 2026 vote
- Advisory committee recommended for the 503A bulks list process
- Reviewed for
- Wound healing
- Current federal 503A list
- Not named in 21 CFR 216.23 as of August 28, 2026
The committee recommended this compound continue in FDA's 503A bulks-list process. That non-binding recommendation was not drug approval, did not itself change federal law, and did not establish safety or effectiveness. The current federal list in 21 CFR 216.23 does not name TB-500.
Why “is it legal” has no yes-or-no answer
Short answer: There is no reliable blanket yes-or-no answer. As of August 28, 2026, TB-500 is not an FDA-approved drug and is not named in the current federal 503A bulks-list regulation at 21 CFR 216.23. Product, prescriber, pharmacy, route, and state-specific facts still matter.
For peptides, access is not a single switch. It depends on the FDA status of the substance, whether a compounding pathway applies, what your state’s pharmacy and medical boards permit, and whether a licensed clinician has evaluated you and written a prescription. Any source giving you a flat yes or no is skipping at least three of those.
TB-500 carries a complication the others do not: it has a long history in athletic and performance circles, and it appears on prohibited-substance lists used by sporting bodies. A compounding recommendation from the FDA has no bearing on whether a sport's governing body permits it, and those two systems are frequently confused.
What the advisory committee actually reviewed
The committee reviewed TB-500 in the context of wound healing. Athletic recovery language - faster healing between training, injury turnaround - is marketing built on top of that, not the reviewed clinical context, and not human outcome proof.
Athletic recovery language is not human outcome proof.
What a committee recommendation is — and is not
The Pharmacy Compounding Advisory Committee advises the FDA. Its recommendations can shape what the agency does next, but the FDA is not required to follow them, and a recommendation is not a drug approval, a safety finding, a prescription, or proof that any clinic can offer something today. The FDA meeting record and the current 21 CFR 216.23 text are the authoritative sources.
Questions people ask
Is TB-500 legal?
There is no reliable blanket yes-or-no answer. As of August 28, 2026, TB-500 is not an FDA-approved drug and is not named in the current federal 503A bulks-list regulation at 21 CFR 216.23. The July 2026 advisory recommendation was non-binding and did not itself change federal law or establish safety or effectiveness. Product, prescriber, pharmacy, route, and state-specific facts still matter.
Does the July 2026 recommendation make TB-500 permitted in competition?
No. Anti-doping rules are set by sporting bodies, entirely separately from FDA compounding policy. If you compete, check your sport's current prohibited list.
What was TB-500 actually reviewed for?
Wound healing. That is the clinical context in the regulatory record.
Is TB-500 FDA approved?
No. It is not an FDA-approved drug product, and the advisory recommendation does not change that.
Why do recovery products reference TB-500?
Because the wound-healing context is easy to restate as athletic recovery. Treat that restatement as a marketing claim and ask for the human evidence behind it.
Finding licensed care
If you want to talk to someone who can actually evaluate your situation, start with a licensed clinic. We list clinics by city and publish what we verified about each one, with the date we verified it.
Clinics we list: Chicago, IL, Indianapolis, IN, Louisville, KY, Las Vegas, NV